The Bitwise NEAR ETF, which holds NEAR Protocol tokens, reported net assets of $86.97 million on October 18, up from $82.36 million on October 15. The fund's NEAR token holdings increased by over 1.1 million tokens during this period, reaching 17.6 million tokens valued at nearly $87 million. Although the net assets closely track the market value of the tokens, these figures do not clarify the exact amount of investor inflows or outflows. The ETF debuted on the NYSE Arca on September 29 and charges a 0.75% management fee under the ticker NRR.
The Bitwise NEAR ETF reported net assets of $86.97 million as of October 18. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 20, 2026 10:41 WIB: out of 50 major cryptocurrencies priced on Pluang, 24 rose and 25 fell today. Notable movers include SAND at Rp1.037 with a 1-day change of -6.64% and Pluang order activity of 44% Sell / 56% Buy, MANA at Rp1.485 with a 1-day change of -3.70% and Pluang order activity of 47% Sell / 53% Buy, and ZIL at Rp39 with a 1-day change of -3.37% and Pluang order activity of 42% Sell / 58% Buy.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
